Education
About Us
Working with TipRanks
Follow Us
Igm Biosciences (IGMS)
:IGMS
IGMS Stock Chart & Stats
Day’s RangeN/A
52-Week Range― - ―
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
IGM Biosciences News
IGMS FAQ
What was Igm Biosciences’s price range in the past 12 months?
Currently, no data Available
What is Igm Biosciences’s market cap?
Currently, no data Available
When is Igm Biosciences’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Igm Biosciences’s earnings last quarter?
Currently, no data Available
Is Igm Biosciences overvalued?
According to Wall Street analysts Igm Biosciences’s price is currently Undervalued.
Does Igm Biosciences pay dividends?
Igm Biosciences does not currently pay dividends.
What is Igm Biosciences’s EPS estimate?
Igm Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Igm Biosciences have?
Currently, no data Available
What happened to Igm Biosciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Igm Biosciences?
Currently, no hedge funds are holding shares in IGMS
Company Description
Igm Biosciences
IGM Biosciences, Inc. is a biotechnology company focused on developing innovative therapies based on its proprietary IgM antibody platform. Founded in 2010, the company operates primarily in the biopharmaceutical sector, concentrating on the design and commercialization of novel therapeutics for the treatment of various cancers and autoimmune diseases. Its core products include IGM-2323, an investigational IgM antibody designed to target specific cancer cells, as well as other pipeline candidates aimed at addressing unmet medical needs.
Ownership Overview
―
Insiders
2.96%
Mutual Funds
― Other Institutional Investors
97.04% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---